Investigating gene variations and IL-35 levels in chronic hepatitis B

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the association between the FNDC5 gene variations and chronic hepatitis B (CHB), focusing on the distribution of its alleles in relation to various clinical parameters. It will also assess the correlation between IL-35 and SOD serum levels with the risk of developing CHB. By analyzing these genetic factors, the study seeks to enhance understanding of the mechanisms underlying the clinical outcomes of HBV infection. The research will involve genotyping patients diagnosed with CHB based on established diagnostic criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients diagnosed as a clinical disease of CHB according to the diagnostic criteria of CHB based on, HBsAg, HBeAg serostatus ,HBV DNA level, biochemical liver function, and ultrasonography

Exclusion Criteria:

* The chronic HBV patients on antiviral therapy will be excluded.

Where it's running

• Sohag university Hospital
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Shimaa Badawy Hemdan, lecturer
• Email: shimaabadwy@med.sohag.edu.eg
• Phone: 01115894759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AHB-137 for chronic hepatitis B in adults on nucleotide analogue therapy

  AHB-137 is being tested to see if it is safe and effective for adults with chronic hepatitis B who are currently on nucleos(t)ide analogue therapy.

  Recruiting Phase 2 AusperBio Therapeutics Inc. · Redwood City, California and 9 other locations · NCT07654283

• Oral and gum health and saliva markers in people with hepatitis B and D

  This project will test whether gum inflammation and specific saliva and gum-fluid markers differ in adults with hepatitis B and D—both those taking bulevirtide and those not—compared with healthy adults.

  Recruiting at 2 sites Research Center of Periodontal-Systemic Interactions · Craiova and 1 other locations · NCT07491848

• Entecavir Resistance Mutations in chronic hepatitis B patients in Turkey

  This study tests whether entecavir resistance mutations can be detected in adults with chronic hepatitis B, and whether prior lamivudine exposure increases the chance of those mutations appearing.

  Recruiting at 2 sites Guven Health Group · Adana and 9 other locations · NCT07459426

• AHB-137 for HBeAg-negative chronic hepatitis B in the Asia–Pacific

  This trial tests whether AHB-137 injections can improve outcomes for adults in the Asia–Pacific with HBeAg-negative chronic hepatitis B who are already on nucleos(t)ide therapy.

  Recruiting at 9 sites Phase 2 AusperBio Therapeutics Inc. · Fitzroy, Victoria and 9 other locations · NCT07370207

• Sequential PEG-IFN for Hepatitis B After RNA-targeted Therapy

  This study tests whether starting or delaying a 24-week course of pegylated interferon helps people with chronic hepatitis B who previously used ASO/siRNA therapies.

  Recruiting at 2 sites Huashan Hospital · Beijing, China and 1 other locations · NCT06923280

• Evaluating a new gene therapy for chronic hepatitis B

  This study is testing a new gene therapy for adults with chronic hepatitis B to see if it is safe and effective in fighting the virus.

  Recruiting at 7 sites Phase 1 Precision BioSciences, Inc. · Boston, Massachusetts and 6 other locations · NCT06680232

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.